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Summanr Low-density lipoprotein (LDL) uptake in gliomas was studied to find out if LDL has potential as a
drug camrer of boron. especially for boron neutron capture therapy. Single photon emission tomography
(SPET) was performed 2 h and 20 h after intravenous injection of autologous 9"9Tc-labelled LDL in four
patients with untreated and five patients with recurrent glioma. 9'Tc-LDL uptake was compared with the
uptake of 9'Tc-labelled human serum albumin (HSA). an established blood pool marker. The intra- and
peritumoral distributions of radioactivity in the SPET images were not identical for radiolabelled LDL and
HSA. The mean LDL tumour to brain ratio, determined from transversal SPET slices at 20h post injection.
was 1.5 in untreated and 2.2 in recurrent gliomas; the corresponding ratios for HSA were 1.6 and 3.4. The
brain to blood ratio remained constant at 2 h and 20 h in both types of tumours. These data are not consistent
with highly selective, homogeneous uptake of LDL in gliomas. However, the different tumoral distribution and
rate of uptake of 9Tc-LDL, as compared with 9'Tc-HSA, indicate that the uptake of LDL is different from
that of HSA and that further studies on the mechanism of LDL uptake in glioma are warranted.
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Brain tumours, about half of which are gliomas, are among
the ten most common human tumours (Fogeiholm et al.,
1984; Cancer Society of Finland, 1992). More than half of
the gliomas are malignant with a median survival time of
about I year (Kalijo et al., 1991). In recent decades there has
been no significant improvement in survival of patients with
malignant glioma in spite of efforts to improve conventional
treatments and to develop new ones. Boron neutron capture
therapy (BNCT) is a relatively new binary therapy utilising
low-energy neutrons and the neutron capture reaction of
boron (Barth and Soloway, 1992). Gliomas have been treated
with BNCI and are still the main target of research in this
field (Barth and Soloway, 1992). BNCT requires sufficiently
high and selective uptake of boron in the tumour tissue. The
boronated agent mainly used in BNCT has been water-
soluble borocaptate (BSH). The tumour to brain (T:Br)
boron concentration ratios obtained with BSH have been
rather low and are apparently dependent on blood flow
(Dewit et al., 1990; Barth and Soloway, 1992; Haritz et al.,
1994). Low-density lipoprotein (LDL), the main cholesterol
carrier in blood, has been suggested as a more selective
vehicle for boron since growing tumour tissue requires
cholesterol for cell membrane synthesis (Kahl and Callaway,.
1989; Laster et al., 1991; Vitols, 1991).
LDL is carried into the cell by a receptor-mediated
mechanism (Brown and Goldstein, 1986). Leukaemic cells,
lung cancers, brain tumours and glioma cell lines have LDL
receptors (Murakami et al., 1990; Rudling et al., 1990; Vitols
et al., 1990, 1992) and LDL has been used for drug delivery
in ovarian cancer therapy trials (Gal et al., 1981; Filipowska
et al., 1992). LDL can be boronated by substituting car-
borane esters of fatty alcohols for core cholesterol esters
(Kahl and Callaway, 1989). The amount of LDL taken up by
gliomas in vivo is not known. High-grade gliomas exhibit vast
morphological, biochemical, immunochemical, biological and
chromosomal heterogeneity (McComb and Bigner, 1984).
Consequently, the LDL receptor status of gliomas in vivo
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cannot be defined by studying glioma cell lines or tumour
homogenates. Lipoprotein metabolism in rodents and rab-
bits, the animals carrying most of the glioma models, is
markedly different from that in humans. For this reason,
most animal data for this mode of drug delivery cannot be
directly applied to human gliomas. In order to evaluate LDL
as a potential carrier agent of boron for BNCT we per-
formed brain scintigraphy on glioma patients after adminis-
tering 9ITc-labelled autologous LDL intravenously and
using 'Tc-labelled human serum albumin (HSA) as a con-
trol.
Patients and methods
Patients
Nine patients with supratentonial glioma participated in this
study after informed consent (Table I). Four patients presen-
ted a previously untreated tumour and five had a recurrent
tumour. Previously untreated tumours were diagnosed by
computerised tomography (CT) and the diagnosis was subse-
quently verified by operation; for recurrent tumours there
was a histological diagnosis available from the previous opera-
tion. All patients with recurrent tumours had received
radiotherapy. The mean age of the patients was 51 years
(range 29-69). All patients were on dexamethasone during
the study. Five patients had slightly elevated serum hepatic
enzyme levels resulting from anticonvulsive medication.
This study was approved by the Ethical Committees of the
Department of Neurology and the Department of
Neurosurgery. Helsinki University Central Hospital.
Radiolabelling ofLDL and HSA
LDL was separated from 50 -00 ml of autologous venous
blood by ultracentrifugation (DHEW. 1974). Human serum
albumin (HSA) was purchased from the Blood Transfusion
Service of the Finnish Red Cross. LDL and HSA were
radiolabelled by direct attachment of 9'Tc via partial reduc-
tion of the thiol groups of protein by ascorbic acid; the
method described by Thakur et al. (1992) was applied with
minor modifications. The average efficiency of the labellingI ftTcULDX k in -
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procedure was 95%. the radionucide punrty was 99.99% and
the radiochemical purity was 95%. The improved efficiency
in labelling with ascorbic acid. as compared with previously
described methods, has been shown to be valid also for the
labelling of other types of proteins with ascorbic acid as a
reducing agent (Thakur and DeFulvio. 1991).
99"Tc-LDL (2-3 mg, 20-35 mCi) and 'Tc-HSA (60-
150 mg, 14-29 mCi) were administered intravenously into a
cubital vein in a solution containing 0.17 M sodium acetate
buffer (pH 7.5) and 0.9% sodium chloride. The 99'Tc-LDL
solution also contained 30-50g 1' unlabelled HSA. On an
average 98.0% (range 95.8-99.2%) of the -Tc activity in
blood samples was attached to protein as measured by trich-
loroacetic acid precipitation at various time intervals. The
study with 99Tc-HSA was performed 2-7 days before the
injection of 9Tc-LDL. One recurrent tumour patient
(number 8) did not undergo the 'Tc-HSA study.
Imaging
CT (Siemens Somatom HiQ, Erlangen. Germany) of the
head, using contrast enhancement, was performed on all
patients prior to the nuclear medicine imaging procedures.
Brain SPET and abdominal planar scintigraphy were per-
formed at 2 h and at 17-21 h after the injection of
radiolabelled protein. Data were acquired with a Picker
DDC4096 square detector gamma camera equipped with a
LEAP collimator (Picker International, Cleveland, OH,
USA). In SPET. 64 40 s frames were collected into a 64 x 64
matrix. Transversal sections (thickness 1.4 cm) parallel to the
orbitomeatal line were reconstructed using NUD SPETS
software (Nuclear Diagnostics, Stockholm, Sweden) with a
modified Shepp-Logan filter and attenuation correction
(y = 0.11 cm-') prior to reconstruction (Larsson, 1980).
Regions of interest (ROI) were drawn manually on the trans-
versal SPET images using information obtained from the CT
scans. An ROI drawn around the tumour area represented
tumour tissue and an ROI of similar size on the contralateral
side represented normal brain tissue, and an ROI around the
superior sagittal sinus represented blood. The background
activity was subtracted when calculating the tumour to brain
(T:Br), tumor to blood (T:B), and brain to blood (Br:B)
ratios from the counts per pixel recorded.
Blood, urine and tumour samples
Blood samples were collected at 0. 10. 20 and 40 min and at
1, 2. 3. 4. 7-9. 10-12. 18-21 and 22-25 h after the injection
of 99Tc-LDL. These data were fitted to the sum of two
exponentials as in an earlier study (Vallabhajosula et al.,
1988). In one patient the blood time-activity curve was
exponential rather than biexponential. Seven patients were
subsequently operated on within 22-25 h of administration
of 'Tc-LDL. Urine samples were collected from two
patients between the injection and operation. Radioactivity in
blood, urine, and tumour samples (wet weight) was measured
with a standard gamma counter (1282 Compugamma, LKB-
Wallac, Turku. Finland).
Statistical analysis
Group differences were analysed with the chi-square test and
correlations were calculated with the least-squares method.
Results
In the SPET images 9Tc-LDL and 99mTc-HSA accumulated
in the tumour area as defined by the CT scan (Figures 1-4).
The distribution ofradioactivity in the tumour areas was not
identical for 'Tc-LDL and 991Tc-HSA, and particularly at
20 h dissimilarities were observed, as can be seen in the three
studies presented in Figures 1-3. The tumour to brain (T:Br)
ratio increased from 2 h to 20 h (Figure 4) in all patients
(Table II). The mean T:Br ratio at 20 h was higher in
Fie 1 Patient no. 3: previously untreated glioblastoma in
right temporal lobe. a. C(T scan. b. 99'Tc-HSA SPET image at
20 h. c. 9'Tc-LDL SPET image at 20 h.
Table I Characteristics of patients with previously untreated and recurrent malignant glioma
Patient Age Histological T pe of Previous no. (Years} Sex diagnosis Location tumnour radiotherapy
1 69 Male Glioblastoma L parieto-occipital Untreated No 2 29 Male Malignant glioma, grade III L frontal Untreated No 3 51 Female Glioblastoma R temporal Untreated No 4 62 Male Glioblastoma R temporoparietal Untreated No
5 43 Male Oligodendroglioma, grade III R frontotemporoparietal Recurrent Yes 6 65 Female Astrocytoma, grade IIIa L frontoparietal Recurrent Yes 7 56 Female Oligodendroglioma, grade III L frontal Recurrent Yes 8 42 Male Astrocytoma, grade III' L frontoparietal Recurrent Yes 9 43 Female Astrocytoma, grade 11 R frontal Recurrent Yes
aPatient was not considered reoperable; the histological diagnosis was from the initial operation. L, left; R. right-
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recurrent tumours than in untreated tumours for both
tracers, although the difference was not statistically signi-
ficant (P>0.3). In recurrent cases the T:Br ratios for radio-
labelled LDL and HSA correlated at 20h, whereas in the
untreated cases there was no correlation (Figure 5). The
mean tumour to blood (T:B) ratio in untreated tumours was
0.7 for both 'Tc-LDL and 99mTc-HSA, in recurrent tumours
the T:B ratio was 0.9 for 9'Tc-LDL and 1.2 for 99'Tc-HSA.
The brain to blood (Br:B) ratio remained constant between
2 h and 20 h for both groups.
The mean half-life of the slow component of the 9'9Tc-
LDL was 21.5 h (range 14-31); the mean half-life of the fast
Figure 2 Patient no. 4: previously untreated glioblastoma in
right temporoparietal area. a, CT scan. b, 99mTc-HSA SPET
image at 20 h. c, 99"Tc-LDL SPET image at 20 h.
component was 19 min (range 4-80) (Figure 6). One day
after the injection of9"Tc-LDL about 35% (range 28-45%)
of the injected radioactivity remained in the circulation.
Urinary excretion was 7.3% and 10.9% of the injected dose
(ID) during the first 24 h in two patients given 99'Tc-
LDL.
The 99'Tc-LDL activity (per tissue wet weight) in the
tumour samples varied from 0.02 to 0.56 mCi g-'
(0.09-2.29 x 10-3% ID g-') the mean being 0.27 mCi g-'
(1.05 x 10-3% ID g-'). There was no correlation between the
T:B ratios derived from the SPET images or the T:B ratio
determined from the tumour samples.
Figure 3 Patient no. 5: recurrent anaplastic oligodendroglioma
in right frontotemporoparietal area. a, CT scan. b, 99mTc-HSA
SPET image at 20 h. c, "mTc-LDL SPET image at 20h.
Table 11 Uptake of radioactivity in gliomas in SPET images after intravenous administration of 99mTc-LDL and 99mTc-HSA
2h SPET 20h SPET
Patient T:Br T:B Br:B T:Br T:B Br:B
no. LDL HSA LDL HSA LDL HSA LDL HSA LDL HSA LDL HSA
1 1.2 1.2 0.5 0.6 0.4 0.5 1.5 1.7 0.8 0.7 0.5 0.4
2 0.9 1.1 0.3 0.6 0.3 0.5 1.1 1.7 0.4 0.5 0.4 0.4
3 1.3 1.7 0.5 0.7 0.4 0.4 1.6 1.8 0.8 1.0 0.5 0.6
4 1.3 1.3 0.5 0.5 0.4 0.4 1.8 1.5 0.7 0.6 0.4 0.4
Mean 1.18 1.33 0.45 0.60 0.38 0.45 1.50 1.68 0.68 0.70 0.45 0.45
5a 1.5 2.3 0.6 1.2 0.4 0.5 2.7 4.8 1.0 1.8 0.4 0.4
6a 0.9 1.0 0.3 0.4 0.3 0.4 1.6 1.3 0.5 0.6 0.3 0.5
ra 1.4 1.7 0.6 1.0 0.4 0.6 1.6 2.8 0.8 1.3 0.5 0.5
8a 1.4 ND 0.6 ND 0.4 ND 2.6 ND 1.2 ND 0.5 ND
ga 1.6 1.3 0.5 0.7 0.3 0.5 2.6 4.5 1.2 1.0 0.5 0.2
Mean 1.36 1.58 0.5 0.83 0.4 0.50 2.22 3.35 0.94 1.18 0.44 0.40
Grand 1.28 ± .24 1.45 ± .43 0.49 ± .12 0.71 ± .26 0.37 ± .05 0.48 ± .07 1.90 ± .58 2.51 ± 1.4 0.82 ± .28 0.94±.44 0.44± .07 0.43 ± .12
mean s.d.
aPatients with recurrent, previously operated and radiated tumours. T:Br, tumour to brain ratio; T:B, tumour to blood ratio; Br:B, brain to
blood ratio; ND, not determined."'Tc.LDIX uptak i ti a i %% J~~~~~~~~~~~~~~~~~ Leppia et4
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Figue 5 Correlation between tumour to brain radioactivity
ratios (T:Br) at 20 h in patients with untreated (-) (R = 0.202)
and recurrent (A) (R = 0.858) glioma administered LDL and
HSA labelled with 9Tc.
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Figue 4 Patient no. 8: recurrent anaplastic astrocytoma in left
frontoparietal area. a, CT scan. b. 99Tc-LDL SPET image at 2 h.
c, 'Tc-LDL SPET image at 20 h.
a
The metabolism of lipoproteins in gliomas is poorly under-
stood and there is no earlier information on the uptake of
LDL in human gliomas in vivo, although LDL radiolabelling
and metabolism in general has been extensively investigated
in humans (Kesaniemi et al., 1983; Lees et al., 1985; Gold-
stein and Brown. 1989; Lees and Lees, 1991; Virgolini et al.,
1991; Leitha et al., 1993). Our observations show that
radiolabelled LDL accumulates in gliomas. The uptake of
labelled LDL was, however, not higher than that of labelled
albumin, a standard blood pool marker, and therefore this
study does not provide conclusive evidence of a homo-
geneous, specific uptake of LDL in gliomas. The observed
differences in the distribution of radioactivity in the tumour
areas in patients given LDL and HSA indicate, nevertheless,
that the mechanism for accumulation of LDL could be
different from that of HSA. Albumin, with a molecular
weight of 66 kDa, is known to diffuse passively through the
disrupted blood-brain barrier (BBB). The molecular weight
of LDL is much higher (3 MDa) and therefore the diffusion
rate through the disrupted BBB is correspondingly slower,
which could explain the somewhat lower T:Br ratio for LDL
than for albumin. The rise in the 99Tc-LDL T:Br ratio
between 2 h and 20 h is probably due primarily to the de-
crease in blood radioactivity with time, but LDL receptor-
mediated uptake may also play a role.
The constant Br:B ratio shows that "Tc-LDL does not
cross the intact BBB. and that the radioactivity in the normal
brain probably reflects the radioactivity in the circulation.
The T:B ratios were quite low in both treated and untreated
tumours. However, previous studies conducted with brain
U
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Fiue 6 a. A typical disappearance curve of 9Tc-LDL from
blood was biexponential in patient no. 1. b. T, for the fast
component was 8.7 min and for the slow component 22 h.
phantoms in this laboratory show that a single-head SPET
camera underestimates the true target-to-non-target ratio in
brain SPET images (Nikkinen et al., 1993). The somewhat
higher T:B ratios in recurrent tumours, compared to un-
treated tumours, are probably due to an additional radiation-
induced disruption of the BBB.
Gliomas are known to be very heterogeneous and often
contain necrotic and cystic components, explaining why
tumou,r activities determined from SPET scans did not cor-
relate with activities measured from tissue samples. Therefore
tissue samples can only be considered representative if taken
from a relatively homogeneous tumour, which is not the case
with gliomas.
In conclusion, this study shows that the magnitude of
9'Tc-LDL accumulation in human malignant glioma is
crTc-LDL ua x ooma
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similar to that of 'Tc-HSA and that the mechanism of
LDL uptake may be mostly passive diffusion, in addition to
a blood pool effect. However, the different intratumoral
distribution of radioactivity in patients given LDL and
albumin, along with the different rate of uptake in the
tumours, shows that the behaviour of these two substances in
gliomas is not identical. Consequently, the uptake of LDL
might therefore result from both non-specific and LDL
receptor-mediated processes. Further studies on cellular and
receptor mechanisms will be needed to elucidate the nature of
LDL uptake into human gliomas.
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